Lupin gets approval for Rufinamide Oral Suspension

21 Dec 2020 Evaluate

Lupin has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration, to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.

Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2124.65 -26.40 (-1.23%)
01-Feb-2026 14:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.80
Dr. Reddys Lab 1199.65
Cipla 1325.70
Zydus Lifesciences 887.35
Lupin 2124.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×